In vitro evaluation of antitumor activity of doxorubicin-loaded nanoemulsion in MCF-7 human breast cancer cells
Source abstract
Abstract
Doxorubicin (DOX) is an anticancer drug used to treat several cancer diseases. However, it has several dose limitation aspects because of its poor bioavailability, hydrophobicity, and cytotoxicity. In this study, five nanoemulsion (NE) formulations, containing soya phosphatidylcholine/polyoxyethylenglycerol trihydroxy-stearate 40 (EU)/sodium oleate as surfactant, cholesterol (CHO) as oil phase, and Tris–HCl buffer (pH 7.22), were produced. The NE droplets morphologies of the entire blank and DOX-loaded formulations, revealed by the transmission electron microscope, were spherical. The droplet sizes of blank NEs, obtained between 2.9 and 6.4 nm, decreased significantly with the increase in the ratio of surfactant-to-oil, whereas the droplets sizes of DOX-loaded NE formulations were significantly higher and found in the range of 7.7–15.9 nm. The evaluation for both blank and DOX-loaded NE formulations proved that the NE carrier had improved the DOX efficacy and reduced its cytotoxicity. It showed that the cell growth inhibition of the breast cancer cells (MCF-7) have exceeded the commercial DOX by a factor of 1.7 with increased apoptosis activity and minimal cytotoxicity against the normal human foreskin cells (HFS). In contrast, commercial DOX was found to exhibit a significant non-selective toxicity against both MCF-7 and HFS cells. In conclusion, we have developed DOX-loaded NE formulations which selectively and significantly inhibited cell proliferation of MCF-7 cells and increased apoptosis.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Protein Interaction Studies and Fluorescence Analysis · Cancer Treatment and Pharmacology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (25)
Show source-provided references
1. Bawarski W, Chidlowsky E, Bharali D, Mousa S (2008) Emerging nanopharmaceuticals. Nanomedicine 4:273–28210.1016/j.nano.2008.06.002 ↗
2. Daocheng W, Mingxi W (2010) Preparation of the core-shell structure adriamycin lipiodol microemulsions and their synergistic anti-tumor effects with diethyldithiocarbamate in vivo. Biomed Pharmacother 64:615–62310.1016/j.biopha.2010.03.001 ↗
3. Desai A, Vyas T, Amiji M (2008) Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J Pharm Sci 97:2745–275610.1002/jps.21182 ↗
4. Duncan R, Vicent M, Greco F, Nicholson R (2005) Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr Relat Cancer 12:S189–S19910.1677/erc.1.01045 ↗
5. Formarize T, Sarmonto V, Silva-junior A, Scarpa M, Santilli C, Olivera A (2006) Doxorubicin bicompatible O/W microemulsion stabilized by mixed surfactant containing soya phosphatidylcholine. Colloids Surf B Biointerfaces 51:54–6110.1016/j.colsurfb.2006.05.005 ↗
6. Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FK, Mumaw VR, Lovings ET, Freeman RH, Gewirtz DA (1994) Induction of differentiation and growth arrest associated with nascent (non-oligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Differ 5:723–733
7. Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–50110.1083/jcb.119.3.493 ↗
8. Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R, Sela M (1975) The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res 35:1175–1181
9. Joseph B, Adam S, Lee J (2011) The slow cell death response when screening chemotherapeutic agents. Cancer Chemother Pharmacol 68:795–80310.1007/s00280-010-1549-9 ↗
10. Kakumanu S, Tagne J, Wilson T, Nicolosi R (2011) A nanoemulsion formulation of dacarbazine reduces tumor size in a xenograft mouse epidermoid carcinoma model compared to dacarbazine suspension. Nanomedicine 7:277–28310.1016/j.nano.2010.12.002 ↗
11. Kotmakchiev M, Cetintas V, Kantarci G (2011) Determining in vitro anticancer activity of mitomycin C loaded microemulsion. Curr Opin Biotechnol 22:S127–S12810.1016/j.copbio.2011.05.416 ↗
12. Kratz F, Beyer U, Collery P, Lechenault F, Cazabat A, Schumacher P, Falken U, Unger C (1998) Preparation, characterization and in vitro efficacy of albumin conjugates of doxorubicin. Biol Pharm Bull 21:56–6110.1248/bpb.21.56 ↗
13. Laginha K, Verwoert S, Charrois G, Allen T (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 11:6944–694910.1158/1078-0432.CCR-05-0343 ↗
14. Mason T, Wilking J, Meleson K, Chang C, Graves S (2006) Nanoemulsions: formation, structure, and physical properties. J Phys Condens Matter 18:R635–R66610.1088/0953-8984/18/41/R01 ↗
15. Ohkawa K, Hatano T, Yamada K, Joh K, Takada K, Tsukada Y, Matsuda M (1993) Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res 53:4238–4242
16. Rapoport N, Nam K, Gupta R, Gao Z, Mohan P, Payne A, Todd N, Liu X, Kim T, Shea J, Scaife C, Parker DL, Jeong E, Kennedy AM (2011) Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions. J Control Release 153:4–1510.1016/j.jconrel.2011.01.022 ↗
17. Seymour L, Ulbrich K, Strohalm J, Kopecek J, Duncan R (1990) The pharmacokinetics of polymer-bound adriamycin. Biochem Pharmacol 39:1125–113110.1016/0006-2952(90)90293-T ↗
18. Siddiqui I, Adhami V, Bharali D, Hafeez B, Asim M, Khwaja S, Ahmad N, Cui H, Mousa S, Mukhtar H (2009) Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 69:1712–171610.1158/0008-5472.CAN-08-3978 ↗
19. Singla AK, Garg A, Aggarwal D (2002) Paclitaxel and its formulations. Int J Pharm 235:179–19210.1016/S0378-5173(01)00986-3 ↗
20. Skehan P, Storeng P, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–111210.1093/jnci/82.13.1107 ↗
21. Su M, Zhao M, Luo Y, Lin X, Xu L, He H, Xu H, Tang X (2011) Evaluation of the efficacy, toxicity and safety of vinorelbine incorporated in lipid emulsion. Int J Pharm 411:188–19610.1016/j.ijpharm.2011.03.028 ↗
22. Talekar M, Ganta S, Singh A, Amiji M, Kendall J, Denny WA, Garg S (2010) Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells. Pharm Res 29:2874–288610.1007/s11095-012-0793-6 ↗
23. Venkateshwarlu I, Prabhakar K, Ali M, Kishan V (2010) Development and in vitro cytotoxic evaluation of parenteral docetaxel lipid nanoemulsions for application in cancer treatment. PDA J Pharm Sci Technol 64:233–241
24. Wang J, Costantino J, Tan-Chiu E, Wickerham D, Paik S, Wolmark N (2004) Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst 96:616–62010.1093/jnci/djhs105 ↗
25. Wang M, Shin D, Simons J, Nie S (2007) Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther 7:833–83710.1586/14737140.7.6.833 ↗